2022
Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]
Rodgers-Melnick S, Lin L, Gam K, Souza de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]. Journal Of Pain Research 2022, 15: 1123-1124. PMID: 35469252, PMCID: PMC9034844, DOI: 10.2147/jpr.s370799.Peer-Reviewed Original Research21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy
Schoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.Peer-Reviewed Original ResearchEffects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study
Rodgers-Melnick S, Lin L, Gam K, de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study. Journal Of Pain Research 2022, 15: 71-91. PMID: 35046718, PMCID: PMC8760983, DOI: 10.2147/jpr.s337390.Peer-Reviewed Original ResearchSickle cell diseaseQuality of lifePreliminary efficacyMT participantsCell diseaseWaitlist controlMusic therapyPROMIS Pain InterferencePROMIS sleep disturbanceMixed methods feasibility studyMusic therapy protocolMethods feasibility studyMusic therapy interventionSelf-management skillsPain interferenceSleep disturbancesTherapy interventionWLC participantsTherapy protocolsDiary completionClinical researchTherapyAdultsEfficacyMixed methods intervention design
2020
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease
Sinha C, Bakshi N, Ross D, Loewenstein G, Krishnamurti L. Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28749-e28749. PMID: 33034129, PMCID: PMC8246626, DOI: 10.1002/pbc.28749.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseasePrimary caregiversSCD complicationsCell transplantationCell diseaseDiminished qualityAutologous hematopoietic progenitor cellsPrimary caregiver reportMajor medical decisionsGene therapyCurative optionSevere complicationsHematopoietic progenitor cellsClinical trialsAcceptable treatmentRecent complicationsComplicationsCaregiver reportsCaregiversProgenitor cellsNormal lifeTransplantationTherapyMedical decisionsPatient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
Hawkins L, Sinha C, Ross D, Yee M, Quarmyne M, Krishnamurti L, Bakshi N. Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study. BMC Pediatrics 2020, 20: 172. PMID: 32305060, PMCID: PMC7165370, DOI: 10.1186/s12887-020-02078-w.Peer-Reviewed Original ResearchConceptsChronic transfusion therapySickle cell diseaseTransfusion therapyCell diseaseHealthcare providersPrevention of complicationsFamily experiencesStroke preventionVenous accessPatient knowledgeChildren 12Future studiesPatient participantsChelation therapySignificant patientFamily burdenSubstantial burdenPatient experiencePatientsSemi-structured interview formatTherapyComplicationsResultsFour themesBurdenInformed decision-making process
2019
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
Farrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.Peer-Reviewed Original ResearchConceptsLow-resource settingsEnd pointClinical trial end pointsTrial end pointsPatient-reported outcomesSickle cell disease clinical trialsPanel of cliniciansSickle cell diseaseMeasurement of cureClinical trialsNovel therapiesCell diseaseConsensus recommendationsGlobal burdenUS FoodBiomarker panelDrug AdministrationAvailable evidenceAmerican SocietyCureRelevant findingsLiterature reviewPainPatientsTherapy
2015
Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
Creary S, Zickmund S, Ross D, Krishnamurti L, Bogen D. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Research Notes 2015, 8: 372. PMID: 26303306, PMCID: PMC4548690, DOI: 10.1186/s13104-015-1344-0.Peer-Reviewed Original Research
2014
A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease
Creary S, Gladwin M, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease. Pediatric Blood & Cancer 2014, 61: 1068-1073. PMID: 24436121, DOI: 10.1002/pbc.24931.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellAntisickling AgentsCell PhoneChildChild, PreschoolDirectly Observed TherapyDrug Administration ScheduleElectronic MailFeedbackFemaleHealth SurveysHumansHydroxyureaMaleMedication AdherenceMicrocomputersPatient SatisfactionPilot ProjectsReimbursement, IncentiveReminder SystemsRewardText MessagingVideo RecordingYoung AdultConceptsSickle cell diseaseMedian medication possession ratioMean corpuscular volumeHU adherenceHydroxyurea adherencePilot studyHemoglobin F percentageMedication possession ratioParticipant satisfactionPossession ratioSecondary outcomesPediatric patientsPrimary outcomeStudy entryClinical outcomesHU useHU therapyOverall participant satisfactionSingle institutionCell diseaseReminder alertsCorpuscular volumeTherapyAdherenceOverall median
2010
Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial
Machado R, Barst R, Yovetich N, Hassell K, Goldsmith J, Woolson R, Gordeuk V, Gibbs S, Little J, Kato G, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Berman-Rosenzweig E, Badesch D, Waclawiw M, Gladwin M. Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial. 2010, a2514-a2514. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2514.Peer-Reviewed Original Research
2009
Severe Sickle Cell Disease—Pathophysiology and Therapy
Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S. Severe Sickle Cell Disease—Pathophysiology and Therapy. Transplantation And Cellular Therapy 2009, 16: s64-s67. PMID: 19819341, PMCID: PMC2832723, DOI: 10.1016/j.bbmt.2009.10.001.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHematopoietic stem cell transplantationMarrow Transplant Research databaseSickle cell disease pathophysiologyStem cell transplantationCare of patientsModalities of therapyConservative managementInternational BloodCell transplantationTreatment modalitiesChronic illnessCell diseaseSCD manifestationsResearch DatabaseDisease pathophysiologyDiseaseTherapySignificant riskPatientsTransplantationBabiesPsychosocial costsModalitiesMorbidity